Table 2 Baseline characteristics of the trial participants
Characteristics | Breast cancer N (%) | HGSOC N (%) | |
|---|---|---|---|
Sex | |||
Female | 9 (100) | 23 (100) | |
Age (years) | |||
Median | 46 | 60 | |
Range | 33–64 | 37–84 | |
ECOG performance status | |||
0 | 6 (67) | 13 (57) | |
1 | 3 (33) | 10 (43) | |
gBRCA status | |||
BRCA negative | 3 (33) | 6 (26) | |
gBRCA 1 | 2 (22) | 10 (44) | |
gBRCA 2 | 4 (45) | 6 (26) | |
Unknown | 0 | 1 (4) | |
Breast Cancer cohort | |||
ER positive | 6 | ||
PR positive | 4 | ||
ER, PR, and HER2 negative | 3 | ||
Lines of prior therapy | |||
1 | 2 (22) | 9 (39) | |
2 | 4 (45) | 8 (35) | |
3 | 3 (33) | 6 (26) | |
Breast Cancer cohort | |||
Prior anthracycline | 7 (78) | ||
Prior taxane/anti-tubulin | 8 (89) | ||
Prior platinuma | 6 (67) | ||
Ovarian Cancer cohort | |||
Lines of prior platinum-based therapy (1/2/3) | 9 (39)/10 (44)/4 (17) | ||
Prior bevacizumab | 6 (26) | ||
Platinum-sensitive at first relapse | 22 (96) | ||
Platinum-sensitive at trial enrolment | 15 (65) | ||
